Introduction: We have performed a study to find out how the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2007, 2011, and 2017 classification system affect the clinical characteristics of COPD patients (Cureus 2022;14(12):e32116). The GOLD 2023 report suggested a new ABE assessment tool that recognises the therapeutic value of exacerbations regardless of symptom severity. To emphasise the clinical importance of exacerbations, the C and D groups (of ABCD tool) have been combined into one ?E? group. The GOLD 2023 document acknowledges that this categorization requires clinical studies. Aims and objectives: To categorise the COPD patients according to ABE classification. Methods: In this cross-sectional observational study, COPD patients' demographics, clinical characteristics, and the exacerbations were documented following GOLD 2023 report. Results: A total of 349 COPD subjects were recruited in this study. The ABCD system categorises 78 COPD patients in group A, 158 in B, 44 in C, and 69 in D. While, ABE classification placed 78 (22.4%) COPD patients in group A, 158 patients (45.3%) in B, and 113 (32.4%) in E. FEV1 (% predicted) decreased from A to E. Group E had a longer illness duration, higher CAT score, higher Modified Medical Research Council (mMRC) dyspnea scale, longer exacerbation history, and more COPD hospitalisations in the previous year than groups A and B. Group E patients were older and had a longer disease duration, a higher mMRC dyspnea scale and CAT, a lower FEV1, and more severe airflow limitation (A and B). Conclusion: Our data shows the distribution of COPD patients' according to ABE classification system which provides a better understanding of COPD.